1·Objective:To synthesize pioglitazone hydrochloride.
目的：合成盐酸吡格列酮。
2·The situation has not been the same with pioglitazone.
这种情况与吡格列酮不同。
3·No difference between rosiglitazone and pioglitazone was apparent.
罗格列酮和匹格列酮间无明显差别。
4·It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
它的部分经费由吡格列酮的制造商武田制药提供。
5·The study by Lincoff et al. reviewed the data from clinical trials of pioglitazone.
来自Lincoff等的研究，重新回顾了来自匹格列酮的一些临床试验的数据。
6·Pioglitazone clearly has fallen on the side of cardiovascular benefits or very close.
吡格列酮明显倾向于心血管获益方面或者非常接近。
7·Rosiglitazone and pioglitazone are part of a group of drugs called thiazolidinediones.
罗格列酮和吡咯列酮同属噻唑烷二酮类。
8·Has some of the bad press and issues with rosiglitazone unfairly affected pioglitazone?
有关罗格列酮的一些负面新闻是否会对吡格列酮有影响？
9·We did not observe similar associations in a secondary analysis evaluating pioglitazone.
我们在第二次罗格列酮分析评估中没有看到类似的相关性。
10·Beginning in 1999, rosiglitazone maleate and pioglitazone hydrochloride were approved for use.
从1999年开始，马来酸罗格列酮和盐酸匹格列酮被批准使用。
1·The study was published on Thursday in The New England Journal of Medicine. It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
该项研究在周四发表于《新英格兰医学杂志》。它的部分经费由吡格列酮的制造商武田制药提供。
2·It was financed in part by Takeda Pharmaceuticals, maker of pioglitazone.
它的部分经费由吡格列酮的制造商武田制药提供。
3·Individual components of the primary end point were all reduced by a similar magnitude with pioglitazone treatment, with HRs ranging from 0.80 to 0.92 (Table 3).
吡格列酮治疗降低了初步终止点中每个结局的发生率(降低的程度相似)，其危害比为0.80至0.92(表3)。
4·TABLE 2 lists the clinical outcome measures in the pioglitazone and control groups of the 19 individual trials.
表2列举了吡格列酮及对照组共19项试验的临床结果。
5·The metformin and pioglitazone are insulin sensitizers so they never lower you blood glucose below normal and the GLP-1 analogues or DPP-IV inhibitors also never lower your blood glucose below normal.
二甲双胍和吡格列酮都是胰岛素增敏剂，因此这两类药物不会导致低血糖，而GLP-1类似物或DPP-IV抑制剂导致低血糖的概率也很低。